SanBio Announces SB623 Regenerative Cell Therapy for Traumatic Brain Injury Has Received Ministry of Health, Labour and Welfare (MHLW) Sakigake Designation

The SanBio Group (SanBio Co., Ltd. and SanBio, Inc.) (TOKYO:4592), a scientific leader in regenerative medicine for neurological disorders, announced today that SB623, a regenerative cell therapy that the Group is developing globally for the treatment of chronic motor...

Asepticys™ Files 510k Submission with U.S. FDA seeking Marketing Clearance for Novel TriFlect™ Disinfection Technology Following Successful Completion of Clinical Trial Requirements

Asepticys LLC, a leading innovator and developer of anti-infective pharmaceutical and consumer healthcare products, today announced the successful completion of multi-site human clinical trials for Asepticys’ novel contact lens care solution containing TriFlect™...
SEARCH FOR STUDIES